Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes

Journal of Pharmacology and Experimental Therapeutics

Volumn 327, Issue 1, 2008, Pages 248-257

  Dennison, Jennifer B ^a   Mohutsky, Michael A ^b   Barbuch, Robert J ^b   Wrighton, Steven A ^b   Hall, Stephen D ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; VINCRISTINE;

ARTICLE; CELL LYSATE; CONTROLLED STUDY; CRYOPRESERVATION; DRUG METABOLISM; DRUG STRUCTURE; GENE EXPRESSION; GENOTYPE; HUMAN; HUMAN CELL; LIVER CELL; LIVER MICROSOME; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CRYOPRESERVATION; CYTOCHROME P-450 CYP3A; GENOTYPE; HEPATOCYTES; HUMANS; METABOLIC CLEARANCE RATE; STEROID HYDROXYLASES; VINCRISTINE;

EID: 52649141149     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.139998     Document Type: Article

References (26)

1. Bhatia S, Sather HN, Heerema NA, Trigg ME, Gaynon PS, and Robison LL (2002) Racial and ethnic differences in survival of children with acute lymphoblastic leukemia. Blood 100:1957-1964.
2. Brown HS, Griffin M, and Houston JB (2007) Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab Dispos 35:293-301.
3. Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, Bumol TF, and Starling JJ (1996) Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 56:4171-4179.
4. Dennison JB, Jones DR, Renbarger JL, and Hall SD (2007) Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther 321:553-563.
5. Dennison JB, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, and Hall SD (2006) Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos 34:1317-1327.
6. Eap CB, Buclin T, Hustert E, Bleiber G, Golay KP, Aubert AC, Baumann P, Telenti A, and Kerb R (2004) Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. Eur J Clin Pharmacol 60:231-236.
7. Hallifax D, Rawden HC, Hakooz N, and Houston JB (2005) Prediction of metabolic clearance using cryopreserved human hepatocytes: kinetic characteristics for five benzodiazepines. Drug Metab Dispos 33:1852-1858.
8. He P, Court MH, Greenblatt DJ, and Von Moltke LL (2005) Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther 77:373-387.
9. Hiratsuka M, Takekuma Y, Endo N, Narahara K, Hamdy S, Kishikawa Y, Matsuura M, Agatsuma Y, Inoue T, and Mizugaki M (2002) Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol 58:417-421.
10. Ho RH and Kim RB (2005) Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 78:260-277.
11. Huang W, Lin YS, McConn DJ, Calamia JC, Totah RA, Isoherranen N, Glodowski M, and Thummel KE (2004) Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 32:1434-1445.
12. Jackson DV Jr, Castle MC, and Bender RA (1978) Biliary excretion of vincristine. Clin Pharmacol Ther 24:101-107.
13. Lange BJ, Bostrom BC, Cherlow JM, Sensel MG, La MK, Rackoff W, Heerema NA, Wimmer RS, Trigg ME, and Sather HN (2002) Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 99:825-833.
14. Le CorreP, Parmer RJ, Kailasam MT, Kennedy BP, Skaar TP, Ho H, Leverge R, Smith DW, Ziegler MG, Insel PA, et al. (2004) Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: bimodal, epistatic influence of cytochrome P450-mediated drug metabolism. Clin Pharmacol Ther 76:139-153.
15. Lu C, Li P, Gallegos R, Uttamsingh V, Xia CQ, Miwa GT, Balani SK, and Gan LS (2006) Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes. Drug Metab Dispos 34:1600-1605.
16. McConn DJ 2nd, Lin YS, Allen K, Kunze KL, and Thummel KE (2004) Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complexforming drugs. Drug Metab Dispos 32:1083-1091.
17. McCune J and Lindley C (1997) Appropriateness of maximum dose guidelines for vincristine. Am J Health Syst Pharm 54:1755-1758.
18. Nelson RL (1982) The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer. Med Pediatr Oncol 10:115-127.
19. Patki KC, Von Moltke LL, and Greenblatt DJ (2003) In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes P450: role of Cyp3a4 and Cyp3a5. Drug Metab Dispos 31:938-944.
20. Perrett HF, Barter ZE, Jones BC, Yamazaki H, Tucker GT, and Rostami-Hodjegan A (2007) Disparity in holoprotein/apoprotein ratios of different standards used for immunoquantification of hepatic cytochrome P450 enzymes. Drug Metab Dispos 35:1733-1736.
21. Pollock B, DeBaun M, Camitta BM, Shuster JJ, Ravindranath Y, Pullen DJ, Land VJ, Mahoney DH Jr, Lauer SJ, and Murphy SB (2000) Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. J Clin Oncol 18:813-823.
22. Renbarger JL, McCammack KC, Rouse CE, and Hall SD (2008) Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer 50:769-771.
23. Sethi VS, Jackson DV Jr, White DR, Richards F 2nd, Stuart JJ, Muss HB, Cooper MR, and Spurr CL (1981) Pharmacokinetics of vincristine sulfate in adult cancer patients. Cancer Res 41:3551-3555.
24. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, and Wrighton SA (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 30:883-891.
25. Xie HG, Wood AJ, Kim RB, Stein CM, and Wilkinson GR (2004) Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5:243-272.
26. Zhou XJ, Placidi M, and Rahmani R (1994) Uptake and metabolism of vinca alkaloids by freshly isolated human hepatocytes in suspension. Anticancer Res 14:1017-1022.